Search results
Your search for Venomil (wasp and bee) returned no results
Showing 1 to 4 of 4 results for venoms (wasp and bee)
Showing 1 to 4 of 4 results for venoms (wasp and bee)
In development Reference number: GID-TA11898 Expected publication date: TBC
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.